MGX (MGX) Stock Analysis
Verdict: AVOID
Critical cash runway exhaustion (<6 months) and widening earnings misses force an impending dilutive capital raise near historic lows.
Investment score: 23/100
The AI model issues an AVOID rating on Metagenomi Therapeutics (MGX) due to severe cash burn, immediate dilution risk, negative operating margins (-415%), and persistent earnings misses.
Peers
| Peer | P/E | P/B | P/S | EV/EBITDA | ROIC % | Net margin % |
|---|---|---|---|---|---|---|
| ELTX | -0.83 | 4.29 | 0.00 | -0.60 | — | 0.00 |
| HOWL | -1.25 | 2.74 | 2.13 | -1.03 | — | -1.65 |
| ANVS | -0.58 | -9.17 | 0.00 | -0.52 | — | 0.00 |
| MCRB | -1.74 | 1.18 | 21.65 | -1.85 | — | -11.93 |
| HRGN | -5.79 | -29.32 | 47.07 | -6.20 | — | -7.78 |